Tumor-Targeted Delivery of IL-2 by NKG2D Leads to Accumulation of Antigen-Specific CD8+ T Cells in the Tumor Loci and Enhanced Anti-Tumor Effects

Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a Recombinant DNA Advisory Committee Symposium Held June 15, 2010

(2011) H. C. J. Ertl et al.   CANCER RESEARCH

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

(2011) Carlos A Ramos et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Using monoclonal antibodies to stimulate antitumor cellular immunity

(2011) Lindy G Durrant et al.   Expert Review of Vaccines

Novel Drug Delivery Systems for Sustained and Targeted Delivery of Anti-Cancer Drugs: Current Status and Future Prospects

(2010) Puneet Utreja et al.   Current Drug Delivery

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery

(2009) Simon R. Best et al.   VACCINE

NKG2D ligands in tumor immunity

(2008) N Nausch et al.   ONCOGENE

Müllerian inhibiting substance type II receptor (MISIIR): A novel, tissue-specific target expressed by gynecologic cancers

(2007) Jamie N. Bakkum-Gamez et al.   GYNECOLOGIC ONCOLOGY